{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:20:58Z","timestamp":1791904858540,"version":"4.3.4"},"reference-count":33,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Antimicrobial resistance in bacteria is frightening, especially resistance in Gram-negative Bacteria (GNB). In 2017, the World Health Organization (WHO) published a list of 12 bacteria that represent a threat to human health, and among these, a majority of GNB. Antibiotic resistance is a complex and relatively old phenomenon that is the consequence of several factors. The first factor is the vertiginous drop in research and development of new antibacterials. In fact, many companies simply stop this R&amp;D activity. The finding is simple: there are enough antibiotics to treat the different types of infection that clinicians face. The second factor is the appearance and spread of resistant or even multidrug-resistant bacteria. For a long time, this situation remained rather confidential, almost anecdotal. It was not until the end of the 1980s that awareness emerged. It was the time of Vancomycin-Resistance Enterococci (VRE), and the threat of Vancomycin-Resistant MRSA (Methicillin-Resistant Staphylococcus aureus). After this, there has been renewed interest but only in anti-Gram positive antibacterials. Today, the threat is GNB, and we have no new molecules with innovative mechanism of action to fight effectively against these bugs. However, the war against antimicrobial resistance is not lost. We must continue the fight, which requires a better knowledge of the mechanisms of action of anti-infectious agents and concomitantly the mechanisms of resistance of infectious agents.<\/jats:p>","DOI":"10.3390\/molecules24173152","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T11:26:22Z","timestamp":1567077982000},"page":"3152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Fight Against Antimicrobial Resistance: We Always Need New Antibacterials but for Right Bacteria"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-5595","authenticated-orcid":false,"given":"Rapha\u00ebl E.","family":"Duval","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, CNRS, L2CM, F-54000 Nancy, France"},{"name":"ABC Platform\u00ae, Facult\u00e9 de Pharmacie, F-54505 Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Grare","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, CHU Toulouse, F-31059 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Demor\u00e9","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, p\u00f4le Pharmacie-St\u00e9rilisation, F-54511 Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"Universit\u00e9 de Lorraine, APEMAC, F-54000 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"ref_1","unstructured":"Infectious Diseases Society of America (2019, August 15). Bag Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews. Available online: https:\/\/www.idsociety.org\/globalassets\/idsa\/policy--advocacy\/current_topics_and_issues\/antimicrobial_resistance\/10x20\/statements\/070104-as-antibiotic-discovery-stagnates-a-public-health-crisis-brews.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Infectious Diseases Society of America (2010). The 10 \u00d7 \u201920 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis., 50, 1081\u20131083.","DOI":"10.1086\/652237"},{"key":"ref_4","unstructured":"World Health Organization (2019, August 15). WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed. Available online: http:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/bacteria-antibiotics-needed\/fr\/."},{"key":"ref_5","unstructured":"World Health Organization (2019, August 15). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available online: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","unstructured":"Review on Antimicrobial Resistance (2019, August 15). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Available online: https:\/\/amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf."},{"key":"ref_8","unstructured":"(2019, August 15). Review on Antimicrobial Resistance. Available online: https:\/\/amr-review.org\/."},{"key":"ref_9","unstructured":"Eurostat (2019, August 15). Statistics Explained. Available online: http:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/File:Demographic_balance,_2016_%28thousands%29.png."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"Infectious Diseases Society of America. 10 \u00d7 \u201920 Progress\u2014development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","unstructured":"U.S. Food & Drug Administration (2019, August 15). Drug Approvals and Databases, Available online: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/default.htm."},{"key":"ref_12","unstructured":"Center Watch (2019, August 15). FDA Approved Drugs for Infections and Infectious Diseases. Available online: https:\/\/www.centerwatch.com\/drug-information\/fda-approved-drugs\/therapeutic-area\/25\/infections-and-infectious-diseases."},{"key":"ref_13","unstructured":"Grare, M. (2009). De la Gen\u00e8se d\u2019une Nouvelle Classe d\u2019Antibact\u00e9riens \u00e0 Base de Polyph\u00e9nols Cycliques de Type Calixar\u00e8ne: \u00c9tudes Mol\u00e9culaire(s), Cellulaires(s) et Structurale(s) en Vue de l\u2019Identification des Cibles d\u2019Action: Le Cas du Para-Guanidino\u00e9thylcalix[4]ar\u00e8ne. [Ph.D. Thesis, Universit\u00e9 de Lorraine]. Available online: http:\/\/docnum.univ-lorraine.fr\/public\/SCD_T_2009_0138_GRARE.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0399-077X(05)83006-9","article-title":"N\u00e9cessit\u00e9 d\u2019approches alternatives dans les strat\u00e9gies d\u2019\u00e9valuation des nouveaux antibiotiques antibact\u00e9riens","volume":"35","author":"Garraffo","year":"2005","journal-title":"Med. Mal. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/CMR.3.3.280","article-title":"Resistance to vancomycin and teicoplanin: An emerging clinical problem","volume":"3","author":"Johnson","year":"1990","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1086\/342570","article-title":"Colistin: An antimicrobial for the 21st century?","volume":"35","author":"Stein","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1089\/mdr.2011.0195","article-title":"Gmc Study Group. In vitro antimicrobial activity of \u201clast-resort\u201d antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates","volume":"18","author":"Jacquier","year":"2012","journal-title":"Microb. Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10096-010-0921-3","article-title":"Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary","volume":"29","author":"Damjanova","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jhin.2010.03.021","article-title":"Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin","volume":"76","author":"Kontopoulou","year":"2010","journal-title":"J. Hosp. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000320943","article-title":"Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: Ineffectiveness of carbapenems and increasing resistance to colistin","volume":"56","author":"Neonakis","year":"2010","journal-title":"Chemotherapy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1469-0691.2011.03572.x","article-title":"Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals","volume":"17","author":"Mezzatesta","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","first-page":"20248","article-title":"Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011","volume":"17","author":"Mammina","year":"2011","journal-title":"Eurosurveillance"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1111\/1469-0691.12070","article-title":"High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality","volume":"19","author":"Capone","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijantimicag.2006.12.012","article-title":"Pandrug-resistant Gram-negative bacteria: The dawn of the post-antibiotic era?","volume":"29","author":"Falagas","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","unstructured":"World Health Organization (2019, August 15). WHO\u2019s First Global Report on Antibiotic Resistance Reveals Serious, Worldwide Threat to Public Health. Available online: http:\/\/www.who.int\/mediacentre\/news\/releases\/2014\/amr-report\/en\/."},{"key":"ref_26","unstructured":"(2019, August 15). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zerbaxa."},{"key":"ref_27","unstructured":"(2019, August 15). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zavicefta."},{"key":"ref_28","unstructured":"(2019, August 15). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem."},{"key":"ref_29","first-page":"e01117","article-title":"In Vivo Emergence of Resistance to Novel Cephalosporin-\u03b2-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 \u03b2-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa","volume":"61","author":"Mulet","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Cabot","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drup.2011.02.003","article-title":"Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now","volume":"14","author":"Aronsson","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"ref_32","unstructured":"U.S. Food & Drug Administration (2019, August 20). Drug Approvals and Databases, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic","volume":"38","author":"Veve","year":"2018","journal-title":"Pharmacotherapy"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/17\/3152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:15:03Z","timestamp":1760188503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/17\/3152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":33,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["molecules24173152"],"URL":"https:\/\/doi.org\/10.3390\/molecules24173152","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]}}}